Evidence map›Paper›PMID 21620874›Full record

ArticleLife sciences2011

Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters.

Romi Ghose, Ozozoma Omoluabi, Adarsh Gandhi, Pranav Shah, Kelley Strohacker, Katie C Carpenter, Brian McFarlin, Tao Guo

Abstract read
In one paragraph

Article in Life sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 108 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Romi GhoseDepartment of Pharmacological and Pharmaceutical Sciences, University of Houston, 1441 Moursund Street, Houston, TX 77030, USA. rghose@uh.edu
Ozozoma Omoluabi
Adarsh Gandhi
Pranav Shah
Kelley Strohacker
Katie C Carpenter
Brian McFarlin
Tao Guo
University of Houston · USHouston Health and Human Services Department · US

Funding

Hepatic drug metabolism in inflammationK01DK076057 · NIDDK · UNIVERSITY OF HOUSTON · PI GHOSE, ROMI · 2006 to 2009
$563k
NIDDK NIH HHS K01 DK076057NIDDK NIH HHS K01DK076057-02
6 · The paper itself

Abstract

aimOur aim is to investigate the molecular mechanism of regulation of gene expression of drug metabolizing enzymes (DMEs) and transporters in diet-induced obesity. MAIN

methodsAdult male CD1 mice were fed diets containing 60% kcal fat (HFD) or 10% kcal fat (LFD) for 14 weeks. RNA levels of hepatic DMEs, transporters and their regulatory nuclear receptors (NRs) were analyzed by real-time PCR. Activation of cell-signaling components (JNK and NF-κΒ) and pro-inflammatory cytokines (IL-1β, IL-6 and TNFα) were measured in the liver. Finally, the pharmacodynamics of drugs metabolized by DMEs was measured to determine the clinical relevance of our findings. KEY

findingsRNA levels of the hepatic phase I (Cyp3a11, Cyp2b10, Cyp2a4) and phase II (Ugt1a1, Sult1a1, Sultn) enzymes were reduced ~30-60% in HFD compared to LFD mice. RNA levels of Cyp2e1, Cyp1a2 and the drug transporters, multidrug resistance proteins, (Mrp)2, Mrp3 and multidrug resistant gene (Mdr)1b were unaltered in HFD mice. Gene expression of the NRs, PXR and CAR and nuclear protein levels of RXRα was reduced in HFD mice. Cytokines, JNK and NF-κΒ were induced in HFD mice. Thus reduction in hepatic gene expression in obesity may be modulated by cross-talk between NRs and inflammation-induced cell-signaling. Sleep time of Midazolam (Cyp3a substrate) was prolonged in HFD mice, while Zoxazolamine (Cyp1a2 and Cyp2e1 substrate)-induced sleep time was unaltered. SIGNIFICANCE: This study demonstrates that gene-specific reductions in DMEs can affect specific drugs metabolized by these enzymes, thus providing a rationale to monitor the effectiveness of drug therapy in obese individuals.

Indexed as

AnimalsAryl Hydrocarbon HydroxylasesArylsulfotransferaseConstitutive Androstane ReceptorCytochrome P-450 CYP3ACytochrome P450 Family 2CytokinesDietary FatsEnzymesGene Expression RegulationGlucuronosyltransferaseImmunoblottingLiverMaleMembrane ProteinsMembrane Transport ProteinsAryl Hydrocarbon HydroxylasesArylsulfotransferaseConstitutive Androstane ReceptorCyp2a4 protein, mouseCyp2b10 protein, mouseCyp3a11 protein, mouseCytochrome P-450 CYP3ACytochrome P450 Family 2CytokinesDietary FatsEnzymesGlucuronosyltransferaseMembrane ProteinsMembrane Transport ProteinsMidazolamNF-kappa BPregnane X ReceptorReceptors, Cytoplasmic and NuclearReceptors, SteroidSteroid HydroxylasesSult1a1 protein, mouseZoxazolamine

Identifiers

PMID21620874
PMCPMC3156825
OpenAlexW2085541402

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.